Dogwood Therapeutics reports Q3 2026 results, Halneuron Phase 2b data due in November
The company completed enrollment in its chemotherapy neuropathy trial and closed a $5 million private placement to fund Phase 3 preparation.
Dogwood Therapeutics announced third quarter 2026 financial results on November 5, 2026. The company completed its Halneuron Phase 2b trial in chemotherapy-induced neuropathy, with top-line results to be announced in November 2026.1
The Phase 2b chemotherapy-induced neuropathic pain study enrolled 239 patients, and top-line results are expected in November 2026.1 Separately, Dogwood has fully enrolled 95 patients in its Phase 2b long-term extension study, which is assessing Halneuron's effect on reducing pain over three months of treatment.1 Patients who completed the 4-week CINP Phase 2b study were eligible to enroll in this 12-week open-label follow-on trial.1 The long-term extension study is expected to be completed in early 2027.1
On the corporate side, Dogwood closed a $5 million private placement with Sealbond Limited, described as its largest shareholder and a subsidiary of CK Life Sciences Int'l., (Holdings) Inc., intended to advance Phase 3 preparatory activities for Halneuron as well as for working capital and general corporate purposes.1
On financing, the company said its cash on hand of $4.9 million, combined with the $5 million private placement, gives it operational runway into the first quarter of 2027.1
CEO Greg Duncan said in the release that Halneuron has shown statistically and/or clinically significant and durable pain reduction in cancer and CINP trials to date, and that if the Phase 2b results due in November are successful, the company believes Halneuron could become the first new therapy for CINP patients in the United States and globally.1 Halneuron has received FDA fast track designation for the treatment of CINP.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.